Introduction
The ubiquitin-proteasome pathway is critical for maintaining the homeostasis of most intracellular proteins in eukaryotic cells. In particular, the 26S proteasome plays a central role in eliminating damaged or misfolded proteins and is responsible for more than 80% of intracellular protein degradation (Palombella et al., 1994) . Cell cycle progression, transcription factor activation, apoptosis, and other cellular events may be directly or indirectly controlled by the ubiquitinproteasome pathway (Palombella et al., 1994; King et al., 1996) . Several important regulators, such as cyclin-dependent inhibitors (p21 and p27), p53, and Bax, are degraded via this pathway (Palombella et al., 1994; Pagano et al., 1995; Li and Dou, 2000) , and inhibiting proteasome activity leads to the accumulation of these proteins and results in cell cycle arrest and apoptosis. Furthermore, evidence has shown that transformed cells are more susceptible than nontransformed cells to proteasome inhibitor-induced apoptosis (Adams, 2002b) . Targeting the proteasome pathway has thus emerged as a novel approach to cancer therapy.
Bortezomib (PS-341, Velcade, Millenium, Boston, MA, USA), a dipeptidyl boronic acid, is a specific and selective inhibitor of 26S proteasome (Adams et al., 1999; Adams, 2002b) . Studies of this drug have established its antitumor activity against a wide range of malignancies, including myeloma, prostate cancer, breast cancer, colon cancer, and lung cancer (Adams, 2002b; Lenz, 2003) . Recently, bortezomib became the first proteasome inhibitor approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. Ongoing clinical trials of bortezomib for prostate cancer and lung cancer have revealed promising results (Lara Jr et al., 2004) . Like other proteasome inhibitors, bortezomib can stabilize several protein, including p21, p27, p53, various transcriptional factors (e.g. c-myc, c-fos, and c-jun), IkBa, cyclins, and some Bcl-2 family members (e.g. Bak and Bax) by inhibiting their degradation (Pei et al., 2003; Lara Jr et al., 2004) . However, the mechanisms of apoptosis induction by bortezomib are not well delineated. To elucidate the mechanisms of bortezomib-mediated apoptosis, we analysed changes of Bcl-2 family members after bortezomib treatment and found that bortezomib induced rapid accumulation of Bik/NBK by preventing its degradation and that Bik/ NBK accumulation correlated with bortezomib cytotoxicity and apoptosis induction.
Results

Rapid accumulation of Bik/NBK by bortezomib in various cancer cells
Several members of the Bcl-2 family, including Bax, Bak, Bcl-2, and Bcl-XL, are known targets of bortezomib (Pei et al., 2003; Lara Jr et al., 2004) . To evaluate which Bcl-2 family members are critically affected by bortezomib treatment, we determined their protein levels in the colon cancer cell lines DLD1, LOVO, SW620, and HCT116 after treatment with 0.1-5.0 mM bortezomib for 6 h. Western blot analysis showed that Bik/NBK expression was rapidly and very noticeably upregulated by bortezomib in all four cell lines (Figure 1a ), even at 0.1 mM. Furthermore, in these cells, bortezomib-induced Bik/NBK accumulation was time dependent: accumulation started within 3 h after treatment and became much stronger over time (Figure 1b) . The levels of other Bcl-2 family members (Bax, Bak, Bcl-2, and Bcl-XL) did not obviously change at any bortezomib concentration or time point.
To evaluate whether bortezomib-induced Bik/NBK accumulation was cell-or tissue-type specific, we performed the same experiment with human lung cancer cell line H1299, and ovarian cancer cell line SKOV3. Bik/NBK accumulation was observed in these two cell lines, although the amount of accumulation varied and depended on endogenous Bik/NBK levels ( Figure 1a ). We observed similar results when we used two other proteasome inhibitors, MG132 and calpain inhibitor I (ALLN), to treat all six cell lines. For example, Bik/ NBK accumulation and apoptosis induction were observed in DLD1 cells treated with 0.5-5 mM of MG132 or 5-20 mM of ALLN in a dose-dependent manner (Figure 1c, d ).
Bortezomib induced Bik/NBK accumulation is NFkBindependent
To further characterize the effect of bortezomib on Bik/ NBK accumulation, we evaluated levels of Bik/NBK or Bax in DLD1, 293 and normal human bronchial epithelial cells (HBE) after treatment with low dose of bortezomib. Bik/NBK accumulation was obvious at 24 h after treatment with 50 nM of bortezomib in all three cells (Figure 2a) . The apoptotic cells detected by SubG1 analysis in those cell samples were 44% (DLD1), 17% (293) and 22% (HBE), respectively. However, at this time point, Bik/NBK accumulation was not detectable in these cells at the dose of 10 nM bortezomib. The apoptotic cells in these cell samples were also low (less than 5%).
We also tested whether Bik/NBK is accumulated after treatment with other chemotherapeutic agents. For this purpose, we compared Bik/NBK levels in DLD1 cells treated with 100 nM of paclitaxel or 50 nM of bortezomib. Western blot analysis showed that Bik/NBK was only barely detectable after treatment with paclitaxel. However, a time-dependent Bik/NBK accumulation was obvious after treatment bortezomib (Figure 2b ). Of note, IC 50 of paclitaxel in DLD1 cells was about 2 nM. A measure of 100 nM paclitaxel is sufficient to induce apoptosis in DLD1 cells at 24 h. This result suggested that bortezomib-mediated Bik/NBK accumulation is not caused nonspecifically by apoptosis.
Proteasome inhibitors were reported to inhibit NFkB activation by blocking proteolysis of the inhibitor protein IkBa (Lin et al., 1995) . To test whether bortezomib-mediated Bik/NBK accumulation was related to functional changes of NFkB, we evaluated IkBa levels in DLD1 after treatment with 0.1-5 mM of bortezomib for 6 h. Unlike Bik/NBK whose accumulation was easily detected under those conditions (Figure 1a ), no obvious change in IkBa levels was detected in all the doses tested ( Figure 2c ). Moreover, nuclear extracts and electrophoretic mobility shift assay (EMSA) (Schmidt et al., 2003) showed no detectable changes in NFkB functionality in DLD1 cells after treatment with 100 nM of bortezomib for 3-24 h or with 10-500 nM of bortezomib for 24 h (Figure 2d ). Thus, treatment with bortezomib did not induce detectable changes in NFkB function and bortezomib-mediated Bik/NBK accumulation is NFkB-independent.
Bortezomib enhancement of Bik/NBK protein stability
As bortezomib inhibits proteasome-mediated protein degradation, bortezomib-mediated Bik/NBK accumulation is likely to be caused by stabilization of the protein.
To test this hypothesis, we treated DLD1 cells with dimethylsulfoxide (DMSO), 1 mM bortezomib, or 5-mM MG132 for 6 h and then add cycloheximide to block protein synthesis in DLD1 cells. Cells were then harvested over time and Bik/NBK levels assessed by Western blot analysis. Bik/NBK protein was rapidly degraded in cells treated with DMSO ( Figure 3a ) and had a mean half-life of about 1 h (Figure 3b ). In contrast, in cells treated with bortezomib or MG132, the Bik/NBK protein level and mean half-life were stable even after 6 h of cycloheximide treatment, indicating that Bik/NBK degradation was blocked by treatment of bortezomib.
Association between bortezomib-induced apoptosis and Bik/NBK accumulation
Bortezomib induced obvious accumulation of Bik/ NBK, and overexpression of Bik/NBK can induce apoptosis in various cancer cells (Boyd et al., 1995; Shimizu and Tsujimoto, 2000) . Thus, it is conceivable that Bik/NBK accumulation contributes to bortezomibinduced apoptotosis. To test whether Bik/NBK accumulation was associated with apoptosis induction, we analysed the release of cytochrome c from DLD1 cells after treatment with 1 mM bortezomib for various times. Release of cytochrome c started within 3 h of treatment and became strong after 18 h ( Figure 4a ). This change was consistent with the time-dependent Bik/NBK accumulation we noted. Similarly, cleavage of caspase-9 and -3 started within 3 h of treatment and became stronger after 18 h ( Figure 4b ). Together, these data suggested that Bik/NBK accumulation was associated with bortezomib-initiated apoptosis in cancer cells.
To further test the correlation between Bik/NBK accumulation and bortezomib-mediated cytotoxicity, we evaluated the effect of Bik/NBK knockdown by siRNA. For this purpose, DLD1 cells were treated with 200 nM siRNA specific for Bik/NBK or luciferase (control) as reported (Hur et al., 2004) . After 24 h, the cells were treated with 1-mM bortezomib. Levels of Bik/NBK protein were determined by Western blot analysis 24 h later. In comparison with control siRNA, pretreatment with Bik/NBK siRNA can dramatically reduce Bik/ NBK protein level (about 50% when determined by band intensity and normalized with b-actin). Nevertheless, treatment with bortezomib resulted in obvious Bik/NBK accumulation in cells pretreated with Bik/ NBK siRNA, although the level of this accumulation was dramatically lower (also about 50%) than that pretreated by control siRNA (Figure 4c ), suggesting that bortezomib-mediated Bik/NBK accumulation was very efficient and can occur when Bik/NBK level was very low. Cell viability analysis showed that treatment with Bik/NBK or control siRNA alone did not lead to cell viability loss. No detectable viability loss was observed at 12 h after addition of bortezomib in all groups (data not shown). Treatment with bortezomib for 24 h led to significant viability loss in all groups. However, in comparison with cells pretreated with phosphate-buffered saline (PBS) or control siRNA, pretreatment with Bik/NBK siRNA significantly reduced bortezomib-mediated cell killing (Figure 4d ) (Po0.01). Thus, reduced level of Bik/NBK accumulation correlates with reduced cell killing by bortezomib.
Association between cancer cell sensitivity to bortezomib and Bik/NBK accumulation Although bortezomib induced accumulation of Bik/ NBK in various cancer cells, the amount of Bik/NBK accumulation in these cell lines varied dramatically (Figure 5a ). To test whether this amount affected the sensitivity of cancer cells to bortezomib, we determined susceptibility of these cells to the treatment of bortezomib by analysing the concentration required to inhibit 50% of cell growth after exposure to this agent for 4 days. The result showed that the cell lines with higher Bik/NBK accumulation (DLD1, LOVO, SW620 and HCT116) had low IC 50 , or were more sensitive to bortezomib treatment than was the cell line with lower Bik/NBK accumulation (SKOV3) (Figure 5b ). Analysis of apoptosis by Annexin V staining revealed a similar result. After treatment with the same concentration of bortezomib, percentage of apoptotic cells detected in LOVO and DLD1 cells were dramatically high, compared to SKOV3 cells (data not shown). The H1299 cell line was an exception: although it had a low level of Bik/ NBK accumulation, it was sensitive to bortezomib.
Discussion
We demonstrated that bortezomib induced rapid and dramatic accumulation of Bik/NBK protein in several cancer cell lines, particularly human colon cancer cell lines, and that this accumulation was due mainly to (Yu et al., 2003 ). However, we tested several cell lines with different p53 status (LOVO and HCT116, wild type, and DLD1 and SW620, mutant) and found no obvious changes in the expression of these two proteins. This result is not consistent with Bax/Bak accumulation in p53 wide-type HCT116 cells that was reported by others (Yu et al., 2003) . It is possible that biological property of the same cell line used in different laboratory may vary. However, because Bax/Bak accumulation upon bortezomib treatment was not observed in all the cell lines tested in this study, such an accumulation may not be a generalized phenomenon. Bortezomib could also inhibit activation of NFkB by preventing degradation of IkBa, leading to downregulation of Bcl-2 and Bcl-XL protein expression (Pei et al., 2003; Lara Jr et al., 2004) . However, we did not find any changes in the expression of Bcl-2 or Bcl-XL in cell lines tested here and observed no substantial accumulation of IkBa after 6 h treatment with 0.1-5 mM bortezomib. NFkB functional assay also did not reveal detectable changes after treatment with bortezomib at various doses and time points. Together, these data indicated that Bik/NBK accumulation after exposure to bortezomib might be a major contribution to apoptosis induction and that p53 and NFkB may not be critical in Bik/NBK accumulation. It remains unclear, however, why only Bik/NBK accumulation was detected after treatment with bortezomib and other proteasome inhibitors. A possible explanation could be that E3 ubiquitin ligase specific for Bik/NBK is more sensitive to these proteasome inhibitors. Further investigation on this issue may provide insight on selective apoptosisinduction in transformed cells by proteasome inhibitors (Adams, 2002a) .
Bik/NBK is reported to interact with Bcl-XL and Bcl-2, and triggers Bax-dependent apoptosis that coincides with cytochrome c release (Gillissen et al., 2003) . Using GFP-tagged cytochrome c to monitor cytochrome c release during apoptosis, Goldstein et al. (2000) showed that release of cytochrome c during apoptosis is rapid, complete and kinetically invariant . In this study, we found cytochrome c release was detectable as early as 3 h after treatment with bortezomib, coinciding with Bik/ NBK accumulation (Figures 1b and 3a) . However, dramatic cytochrome c was detected at 18 h after bortezomib treatment. Whereas the cytochrome c release reported by Goldstein et al. (2000) represents a process occurring at a single-cell level, the cytochrome c release detected in this study represents a process for whole population of cells in culture. It is likely that response to bortezomib in cultured cells is not a synchronized process. Apoptosis may occur at early time points in a few cells but increase dramatically over time. Results from our six different cell lines showed that the amount of Bik/NBK accumulation is generally associated with the cells susceptibility to bortezomib. The exception was H1299 cells, which expressed a low level of endogenous Bik/NBK but were sensitive to bortezomib. In H1299 cells, Bik/NBK accumulation after bortezomib treatment was detectable but not as dramatic as that in the other cell lines. Bax and Bak were detected in this cell line, however, not accumulated after bortezomib treatment. One explanation is that low accumulation of Bik/ NBK is sufficient to kill H1299 cells or suppress their growth. In fact, using a GFP/Bik fusion construct, we have previously reported that detectable expression of exogenous Bik (green color) was sufficient to induce cell death in all cells we have tested (Kagawa et al., 2001) , suggesting that apoptosis induction by Bik is potent and effective. Alternatively, proteins other than Bik/NBK may contribute to the cell killing activities of proteasome inhibitors in these cells. Interestingly, although H1299 is sensitive to bortezomib by cell viability assay, apoptotic cells detectable by Sub-G1 assay was only less than 5% at 24 h after treatment with 0.1-1 mM of bortezomib. Treatment with Bik/NBK siRNA has no significant impact on bortezomib-mediated cell killing in H1299 cells (data not shown). Thus, it is possible that Bik/NBK accumulation and apoptosis-induction is one but not the sole mechanism of proteasome inhibitor-mediated antitumor activity. As a large number of cellular proteins are degraded by ubiquitin/proteasome pathway, it is not unexpected that inhibition of proteasome will alter the levels of a variety of proteins, including many molecules that may induce cell death or suppress cell proliferation, but are not analysed in this paper. Nevertheless, the generally dramatic accumulation of Bik/NBK in all cancer cell lines after treatment with proteasome inhibitors and its association with apoptosis induction may provide useful information for evaluating bortezomib-based cancer therapy.
Materials and methods
Cells and cell culture
Human colon cancer cell lines DLD1, LOVO, SW620, and HCT116; human lung cancer cell lines H1299; human ovarian cancer cell line SKOV3; and human embryonic kidney 293 cells were maintained in RPMI 1640 or Dulbecco's modified Eagle's medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 1% glutamine and 1 Â antibioticsantimycotics mixture (Invitrogen, Carlsbad, CA, USA). Human bronchial epithelial cells were purchased from Clonetics (San Diego, CA, USA) and cultured in media recommended by the manufacturer. All cells were cultured at 371C in a humidified incubator containing 5% CO 2 .
Chemicals
Bortezomib was obtained from the Pharmacy of The University of Texas MD Anderson Cancer Center and dissolved in PBS at 5 mM as a stock solution. Proteasome inhibitor MG132 and ALLN were purchased from Calbiochem (La Jolla, CA, USA) and diluted in DMSO at stock concentrations of 10 and 20 mM, respectively. Cycloheximide and DMSO were bought from Sigma (St Louis, MO, USA).
Western blot analysis
Cells were lysed in Laemmli's lysis buffer. Equal amounts of lysate were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subjected to Western bloting, as described previously (Wu et al., 2003) . Rabbit anti-human Bik/NBK, Bcl-XL, Bcl-2, Bax, caspase-3, and caspase-9 antibodies and goat antihuman antibody Bak were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-human cytochrome c and COX4 antibodies were bought from BD Pharmingen (San Diego, CA, USA). Mouse anti-human b-actin antibody was obtained from Sigma and was used as a loading control.
Extraction of cytosol
Cells (1 Â 10 6 ) were plated onto 10-cm dishes, incubated overnight, and then treated with 1 mM bortezomib for various times. The medium was removed and cells were trypsinized and collected into Eppendorf tubes. After being washed with PBS once, cells were resuspended with 100 ml of digitonin buffer (0.02% digitonin, 5-mM EDTA, 1 mM Phenylmethylsulfonyl fluoride (PMSF), 75-mM sucrose, 25-mM NaCl, 2.5-mM PIPES, 0.75-mM MgCl 2 Á 6H 2 O), incubated on ice for 10 min and then spun at 10 000 r.p.m. for 25 min. The supernatants were collected as cytosol components. Mitochondria were extracted as previously reported (Wu et al., 2003) and were used as a control.
Nuclear extracts and EMSA EMSAs were performed as described (Schmidt et al., 2003) . 32 P-labeled double-stranded oligonucleotides containing the kB site (underlined) found in the HIV-1 LTR (5 0 -CTCAACAGAGGG GACTTTCCGAGAGGCCAT-3 0 ) were incubated as probes. Unlabeled double-stranded oligonucleotides (50-fold molar excess) containing the mutant HIV-kB (5 0 -CTCAACAGA GTTGACTTTTCGAGAGGCCAT-3 0 ) and wild-type HIVkB were used for competition studies. For antibody supershifts, 2 ml of the polyclonal antibodies against p65 and p50 (Santa Cruz Biotechnology) were preincubated for 30 min at room temperature before the probe was added. The probe was allowed to bind for 20 min on ice. Reaction mixtures were analysed on 4% polyacrylamide gels containing 0.25 Â TBE (22.5 mM Tris, 22.5 mM borate, 0.5 mM EDTA, pH 8.0) buffer.
Cell viability assay
Cell viability was determined by seeding 4 Â 10 3 cells/well in 96-well plates, incubating them for 1 day, treating them with bortezomib (0.01-100 mM) continuously for 4 days. Cell viability was then determined by 3-bis-(2-methoxy-4-nitro-5-sulfenyl)-(2H)-tetrazolium-5-carboxanilide (XTT) assay (Cell Proliferation Kit; II, Roche Molecular Biochemicals, Indianapolis, IN, USA), as described previously (Wu et al., 2003) .
siRNA transfection
The sequences for oligodubplex Bik siRNA was the same as reported (Hur et al., 2004) . Both Bik siRAN and control luciferase siRNA were obtained from Dharmacon (Lafayette, CO, USA). Transfection of siRNA was performed using Oligofectamine (Invitrogen) according to the manufacturer 0 s instruction.
Protein stability assay
To determine protein stability, we treated cells with DMSO, MG132, or bortezomib for up to 6 h and then added 25-mg/ml cycloheximide to block protein synthesis (Kim et al., 2002) . Collected protein samples were subjected to Western blot analysis using anti-Bik/NBK antibody. Band densities were qualified using Optimas software (Media Cybernetics, Silver Spring, MD, USA), and the mean half-life of Bik/NBK was calculated.
Abbreviations ALLN, calpain inhibitor I; DMSO, dimethylsulfoxide; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; XTT, 3-bis-(2-methoxy-4-nitro-5-sulfenyl)-(2H)-tetrazolium-5-carboxanilide.
